US · Healthcare · Health Information Services
EPS came in at -0.21 against a street estimate of -0.32 — a beat of 34.4%.
Analysts rate Tempus AI, Inc. Class A Common Stock a buy (10 buy, 9 hold, 1 sell out of 20) with an average price target of $75.72.
CONFIDENT TEM delivered 22% revenue growth to $382.5M, raised FY26 guidance to $1.595–1.605B (+25% YoY). FDA approval of xT CDx unlocks ~$85M ASP uplift in 2027; xF liquid biopsy in FDA review with $550 additional ASP expected. Personalis MRD acquisition announced; data/apps segment grew 28% YoY. Q2 2026 Call did not segment revenue by geography. Analysts pressed xF pricing evolution (Rogers clarified Guardant comp justifies higher ADLT), Personalis termination risk (Lefkofsky cited cash/stock levers and deal attractiveness to Personalis), and data deal economics (confirmed no revenue recognition shift, only platform stickiness). Management expressed high confidence in close and data momentum. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| ARK Investment Management LLC | 5.50% |
| BlackRock Inc | 4.55% |
| Baillie Gifford & Co Limited. | 4.49% |
| SoftBank Group Corp | 2.97% |
| JPMorgan Chase & Co | 2.74% |
| Vanguard Capital Management, LLC | 2.74% |
| Vanguard Portfolio Management, LLC | 2.70% |
| Amova Asset Management Americas, Inc | 2.24% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $411.537 million, up from $334.206 million in the third quarter of 2025. • Nine-month 2026 revenue | 2026-11-02 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue increased 23% year over year to $411.5 million. • Gross profit increased 27% to $266.7 million. • Adjusted EBITD | 2026-11-02 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • Tempus AI entered agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand use of Tempus’s de-identified, multimodal rea | 2026-10-23 |
| Quarterly report · Q2 2026 TEMPUS AI, INC. — 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total net revenue (6 months ended June 30, 2026): $730.6 million vs. $570.4 m | 2026-07-30 |
| Results announced · Q3 2026 TEMPUS AI, INC. – Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $382.5 million (Q2 2026), up 22% year-over-year • Full-year 2026 revenue | 2026-07-30 |
| Material agreement · Q3 2026 TEMPUS AI, INC. — MERGER AGREEMENT WITH PERSONALIS, INC. Form 8-K Filed July 20, 2026 --- HEADLINE NUMBERS • Merger Consideration (Cash Component): | 2026-07-20 |
| Reg FD disclosure · Q3 2026 TEMPUS AI, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Announcement Date: July 20, 2026 • Company: Tempus AI, Inc. (Nevada corporation, ticker: TEM, | 2026-07-20 |
| Shareholder vote results · Q2 2026 TEMPUS AI, INC. - 8-K SUMMARY (MAY 21, 2026) HEADLINE NUMBERS • Annual Meeting of Stockholders held on May 21, 2026 • Company has dual-class share s | 2026-05-22 |
Readable in the app.
| Announcement | Date |
|---|---|
| Full-year 2026 revenue guidance raised to $1.60–$1.605 billion Tempus reported a strong third quarter for 2026. Revenue rose 23% year over year to $411.5 million, with Diagnostics revenue up 20% to $303.5 million and Data and Applications revenue up 33% | 2026-11-02 |
| Agreements expand use of de-identified real-world data, analytics software, agentic tools, and machine learnin Tempus AI announced multi-year agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of Tempus’s de-identified oncology and neurology data, analysis software, and AI too | 2026-10-23 |
| Revenue guidance raised to $1.595-$1.605 billion for 2026 Tempus AI reported strong Q2 2026 results with 22% year-over-year revenue growth to $382.5 million. Key highlights include accelerating oncology diagnostics volume growth (31% YoY), strong d | 2026-07-30 |
| Proposed transaction and merger agreement between two companies Tempus and Personalis announced a proposed merger. This 8-K filing is primarily a forward-looking statements disclaimer, outlining risks and uncertainties rather than disclosing deal specifi | 2026-07-20 |
| Entered into merger agreement with Personalis, Inc. Tempus AI announced on July 20, 2026 that it has agreed to acquire Personalis, Inc. in an all-stock or mixed stock-and-cash merger transaction. Under the deal, Personalis shareholders will r | 2026-07-20 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tempus AI, Inc. Class A Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.